Testosterone in prostate cancer: The Bethesda consensus

BJU International

Volumn 110, Issue 3, 2012, Pages 344-352

  Djavan, Bob ^a   Eastham, James ^b   Gomella, Leonard ^c   Tombal, Bertrand ^d   Taneja, Samir ^a   Dianat, Seyed Saeid ^a   Kazzazi, Amir ^a   Shore, Neal ^e   Abrahamsson, Per Anders ^f   Cheetham, Philippa ^g   Moul, Judd ^h   Lepor, Herbert ^a   Crawford, E David ⁱ  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^e Carolina Urologic Research Center   (United States)

^f LUND UNIVERSITY HOSPITAL   (Sweden)

^g Department of Medicine   (United States)

^h DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF COLORADO   (United States)

Author keywords

castration level; castration resistance; hormonal therapy; intermittent androgen deprivation; prostate cancer; serum testosterone

Indexed keywords

ABARELIX; ANDROGEN; ANDROGEN RECEPTOR; BICALUTAMIDE; CETRORELIX; DEGARELIX; FLUTAMIDE; GANIRELIX; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GOSERELIN; HISTRELIN; LEUPRORELIN; TESTOSTERONE; TRIPTORELIN;

ANDROGEN DEPRIVATION THERAPY; CANCER CELL; CANCER RADIOTHERAPY; CANCER STEM CELL; CANCER SURGERY; CASTRATION; CASTRATION RESISTANT PROSTATE CANCER; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; HORMONE DETERMINATION; HUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REVIEW; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION;

ANDROGEN ANTAGONISTS; ANDROGENS; CHOLESTENONE 5 ALPHA-REDUCTASE; CONSENSUS; CYCLOOXYGENASE 2 INHIBITORS; DISEASE PROGRESSION; HUMANS; MALE; METABOLIC NETWORKS AND PATHWAYS; NEOPLASTIC STEM CELLS; ORCHIECTOMY; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; TESTOSTERONE; THERAPIES, INVESTIGATIONAL;

EID: 84863728731     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10719.x     Document Type: Review

References (68)

1. Huggins C, Hodges CV,. Studies on prostatic cancer I. The effect of castration, of estrogen, and of androgen injection on serum phosphatises in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-7
2. Roddam AW, Allen NE, Appleby P, et al,. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008; 100: 170-83 (Pubitemid 351480553)
3. Xylinas E, Ploussard G, Durand X, et al,. Low pretreatment total testosterone (<3 ng/mL) predicts extraprostatic disease in prostatectomy specimens from patients with preoperative localized prostate cancer. BJU Int 2011; 107: 1400-3
4. Gomella LG,. Effective testosterone suppression for prostate cancer: is there a best castration therapy? Rev Urol 2009; 11: 52-60
5. Sharifi N, Gulley JL, Dahut WL,. Androgen deprivation therapy for prostate cancer. JAMA 2005; 294: 238-44 (Pubitemid 41043794)
6. Crawford ED, Rove KO,. Incomplete testosterone suppression in prostate cancer. N Engl J Med 2010; 363: 1976
7. Sugiono M, Winkler MH, Okeke AA, et al,. Bicalutamide vs cyproterone acetate in preventing flare with LHRH analogue therapy for prostate cancer-a pilot study. Prostate Cancer Prostatic Dis 2005; 8: 91-4
8. Sharifi R, Bruskewitz RC, Gittleman MC, et al,. Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer. Clin Ther 1996; 18: 647-57 (Pubitemid 26323042)
9. Sharifi R, Knoll LD, Smith J, et al,. Leuprolide acetate (30-mg depot every four months) in the treatment of advanced prostate cancer. Urology 1998; 51: 271-6 (Pubitemid 28093180)
10. Sharifi R, Browneller R,. Serum testosterone suppression and potential for agonistic stimulation during chronic treatment with monthly and 3-month depot formulations of leuprolide acetate for advanced prostate cancer. J Urol 2002; 168: 1001-4
11. Zinner NR, Bidair M, Centeno A, et al,. Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6 mg and 10.8 mg: results of a randomized open-label trial. Urology 2004; 64: 1177-81 (Pubitemid 39647062)
12. Khan MS, O'Brien A,. An evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostate. Urol Int 1998; 60: 33-40 (Pubitemid 28072437)
13. Jocham D,. Leuprorelin three-month depot in the treatment of advanced and metastatic prostate cancer: long-term follow-up results. Urol Int 1998; 60 (Suppl. 2): 18-24; discussion 35
14. Yri OE, Bjoro T, Fossa SD,. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. Eur Urol 2006; 49: 54-8 (Pubitemid 41789955)
15. Seidenfeld J, Samson DJ, Hasselblad V, et al,. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000; 132: 566-77 (Pubitemid 30171897)
16. Morote J, Esquena S, Abascal JM, et al,. Behavior of free testosterone in patients with prostate cancer on androgen deprivation therapy. Int J Biol Markers 2005; 20: 119-22 (Pubitemid 41052457)
17. Zherdev AV, Byzova NA, Izumrudov VA, et al,. Rapid polyelectrolyte-based immunofiltration technique for testosterone detection in serum samples. Analyst 2003; 128: 1275-80 (Pubitemid 37357604)
18. Klotz L, Boccon-Gibod L, Shore ND, et al,. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008; 102: 1531-8
19. Oefelein MG, Feng A, Scolieri MJ, et al,. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 2000; 56: 1021-4
20. Tombal B, Berges R,. Optimal control of testosterone: a clinical case-based approach of modern androgen-deprivation therapy. Eur Urol Suppl 2008; 7: 15-21 (Pubitemid 350267365)
21. Morote J, Esquena S, Abascal JM, et al,. Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer. Urol Int 2006; 77: 135-8 (Pubitemid 44195773)
22. Morote J, Orsola A, Planas J, et al,. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol 2007; 178: 1290-5 (Pubitemid 47368393)
23. Morote J, Planas J, Salvador C, et al,. Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy. BJU Int 2009; 103: 332-5; discussion 335
24. Perachino M, Cavalli V, Bravi F,. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance? BJU Int 2010; 105: 648-51
25. National Comprehensive Cancer Network I. NCCN Guidelines in Oncology, Prostate cancer- v.1.2010. 2010
26. Heidenreich A, Bolla M, Joniau S, et al,. Guidelines on prostate cancer. 2010
27. Soldin SJ, Soldin OP,. Steroid hormone analysis by tandem mass spectrometry. Clin Chem 2009; 55: 1061-6
28. Vesper HW, Botelho JC,. Standardization of testosterone measurements in humans. J Steroid Biochem Mol Biol 2010; 121: 513-9
29. Wolff JM, Tunn UW,. Intermittent androgen blockade in prostate cancer: rationale and clinical experience. Eur Urol 2000; 38: 365-71
30. Abrahamsson PA,. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur Urol 2010; 57: 49-59
31. Oefelein MG,. Health related quality of life using serum testosterone as the trigger to re-dose long acting depot luteinizing hormone-releasing hormone agonists in patients with prostate cancer. J Urol 2003; 169: 251-5 (Pubitemid 35461599)
32. Pathak AS, Pacificar JS, Shapiro CE, et al,. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study. J Urol 2007; 177: 2132-5; discussion 2135 (Pubitemid 46726422)
33. Greil S, Robinson EA, Singal B, et al,. Efficacy over time of LHRH analogs in the treatment of PCa-a prospective analysis using serum testosterone to determine dosing intervals. Urology 2009; 73: 631-4
34. Blumberg JM, Kwon EO, Cheetham TC, et al,. Early development of castrate resistance varies with different dosing regimens of luteinizing hormone releasing hormone agonist in primary hormonal therapy for prostate cancer. Urology 2011; 77: 412-6
35. D'Amico AV, Renshaw AA, Loffredo B, et al,. Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy. Cancer 2007; 110: 1723-8 (Pubitemid 47557296)
36. Horwitz EM, Bae K, Hanks GE, et al,. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008; 26: 2497-504
37. D'Amico AV, Chen MH, Renshaw AA, et al,. Interval to testosterone recovery after hormonal therapy for prostate cancer and risk of death. Int J Radiat Oncol Biol Phys 2009; 75: 10-5
38. Yu EY, Gulati R, Telesca D, et al,. Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation. J Clin Oncol 2010; 28: 2668-73
39. Hussain M, Tangen CM, Higano C, et al,. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006; 24: 3984-90 (Pubitemid 46630748)
40. Hussain M, Goldman B, Tangen C, et al,. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol 2009; 27: 2450-6
41. Hellerstedt BA, Pienta KJ,. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 2002; 52: 154-79 (Pubitemid 34546107)
42. Scher HI, Sawyers CL,. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005; 23: 8253-61 (Pubitemid 46211563)
43. Dutt SS, Gao AC,. Molecular mechanisms of castration-resistant prostate cancer progression. Future Oncol 2009; 5: 1403-13
44. Dehm SM, Tindall DJ,. Regulation of androgen receptor signaling in prostate cancer. Expert Rev Anticancer Ther 2005; 5: 63-74 (Pubitemid 40287437)
45. Feldman BJ, Feldman D,. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1: 34-45 (Pubitemid 33741879)
46. Pienta KJ, Bradley D,. Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 2006; 12: 1665-71
47. Thomas LN, Lazier CB, Gupta R, et al,. Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer. Prostate 2005; 63: 231-9 (Pubitemid 40571057)
48. Thomas LN, Douglas RC, Rittmaster RS, et al,. Overexpression of 5 alpha-reductase type 1 increases sensitivity of prostate cancer cells to low concentrations of testosterone. Prostate 2009; 69: 595-602
49. Holzbeierlein J, Lal P, LaTulippe E, et al,. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004; 164: 217-27 (Pubitemid 38364606)
50. Edwards J, Krishna NS, Witton CJ, et al,. Gene amplifications associated with the development of hormone-resistant prostate cancer. Clin Cancer Res 2003; 9: 5271-81 (Pubitemid 37413579)
51. Donkena KV, Yuan H, Young CY,. Recent advances in understanding hormonal therapy resistant prostate cancer. Curr Cancer Drug Targets 2010; 10: 402-10
52. Bonkhoff H, Berges R,. From pathogenesis to prevention of castration resistant prostate cancer. Prostate 2010; 70: 100-12
53. Chen CD, Welsbie DS, Tran C, et al,. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10: 33-9 (Pubitemid 38524696)
54. Gregory CW, He B, Johnson RT, et al,. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001; 61: 4315-9 (Pubitemid 32685750)
55. Narayanan BA, Reddy BS, Bosland MC, et al,. Exisulind in combination with celecoxib modulates epidermal growth factor receptor, cyclooxygenase-2, and cyclin D1 against prostate carcinogenesis: in vivo evidence. Clin Cancer Res 2007; 13: 5965-73 (Pubitemid 47583925)
56. Debes JD, Tindall DJ,. Mechanisms of androgen-refractory prostate cancer. N Engl J Med 2004; 351: 1488-90 (Pubitemid 39315314)
57. Collins AT, Berry PA, Hyde C, et al,. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65: 10946-51 (Pubitemid 41713363)
58. Mostaghel EA, Montgomery B, Nelson PS,. Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease. Urol Oncol 2009; 27: 251-7
59. Mohler JL, Gregory CW, Ford OH 3rd, et al,. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004; 10: 440-8 (Pubitemid 38173980)
60. Mizokami A, Koh E, Fujita H, et al,. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res 2004; 64: 765-71 (Pubitemid 38120921)
61. Koh E, Kanaya J, Namiki M,. Adrenal steroids in human prostatic cancer cell lines. Arch Androl 2001; 46: 117-25 (Pubitemid 32202486)
62. Locke JA, Guns ES, Lubik AA, et al,. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008; 68: 6407-15
63. Leon CG, Locke JA, Adomat HH, et al,. Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model. Prostate 2010; 70: 390-400
64. Takayanagi A, Masumori N, Hashimoto J, et al,. Effect of delayed maximal androgen blockade therapy for patients with advanced prostate cancer who fail to respond to initial androgen deprivation monotherapy. Jpn J Clin Oncol 2010; 40: 1154-8
65. Hashimoto K, Masumori N, Hashimoto J, et al,. Serum testosterone level to predict the efficacy of sequential use of antiandrogens as second-line treatment following androgen deprivation monotherapy in patients with castration-resistant prostate cancer. Jpn J Clin Oncol 2011; 41: 405-10
66. Kawata H, Ishikura N, Watanabe M, et al,. Prolonged treatment with bicalutamide induces androgen receptor overexpression and androgen hypersensitivity. Prostate 2010; 70: 745-54
67. Chen Y, Clegg NJ, Scher HI,. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol 2009; 10: 981-91
68. Montgomery RB, Mostaghel EA, Vessella R, et al,. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008; 68: 4447-54